Ann Arbor, MI (July 23, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today the launch of CE-IVD assays for Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV). Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) are herpes viruses found in up to 90% of the adult population.  Usually latent, the presence...

Ann Arbor, MI (June 21, 2019) – NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today the launch of CE-IVD assays for Hepatitis B virus (HBV) and Hepatitis C virus (HCV). Hepatitis infections are more frequent in immunocompromised populations than in the general population with lower rates of spontaneous recovery...

If you’re in Savannah, Georgia this week for the American Society for Microbiology’s Clinical Virology Symposium, NeuMoDx™ teammate Jason has a message for you! Stop by booth #547 now through Wednesday, May 8 at #ASMCVS – we can’t wait to show you the future of molecular diagnostics.

NeuMoDx™ Molecular was recently at ECCMID displaying our NeuMoDx™ Molecular 288 System. Our system is capable of automated extraction and isolation of nucleic acids from multiple specimen types, as well as the automated amplification and detection of target nucleic acid sequences by fluorescence-based PCR. Listen to Jeff Williams, Chairman and CEO of NeuMoDx™ Molecular, explain why the NeuMoDx™ system is...